Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Hits Above The Belt With Zantac Purchase

This article was originally published in The Tan Sheet

Executive Summary

Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business

You may also be interested in...



Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales

Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare

Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales

Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare

Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales

Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS099841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel